Aims Recent evidence supports the occurrence of multiple hormonal and metabolic deficiency syndrome (MHDS) in chronic heart failure (CHF). However, no large observational study has unequivocally demonstrated its impact on CHF progression and outcome. The T.O.S.CA. (Trattamento Ormonale nello Scompenso CArdiaco; Hormone Treatment in Heart Failure) Registry has been specifically designed to test the hypothesis that MHDS affects morbidity and mortality in CHF patients. Methods The T.O.S.CA. Registry is a prospective, multicentre, observational study involving 19 Italian centres. Thyroid and Results hormones, insulin-like growth factor-1, total testosterone, dehydropianoandrosterone sulfate, insulin resistance, and the presence of diabetes were evaluated. A MHDS was defined as the presence of ≥2 hormone deficiencies (HDs). Primary endpoint was a composite of all-cause mortality and cardiovascular hospitalizations. Four hundred and eighty heart failure patients with ejection fraction ≤45% were enrolled. MHDS or diabetes was diagnosed in 372 patients (77.5%). A total of 271 events (97 deaths and 174 cardiovascular hospitalizations) were recorded, 41% in NO-MHDS and 62% in MHDS (P < 0.001). Median follow-up was of 36 months. MHDS was independently associated with the occurrence of the primary endpoint [hazard ratio 95% (confidence interval), 1.93 (1.37–2.73), P < 0.001] and identified a group of patients with a higher mortality [2.2 (1.28–3.83), P = 0.01], with a graded relation between HDs and cumulative events (P < 0.01). Conclusion MHDS is common in CHF and independently associated with increased all-cause mortality and cardiovascular hospitalization, representing a promising therapeutic target.

Multiple hormonal and metabolic deficiency syndrome predicts outcome in heart failure: the T.O.S.CA. Registry / Cittadini A.; Salzano A.; Iacoviello M.; Triggiani V.; Rengo G.; Cacciatore F.; Maiello C.; Limongelli G.; Masarone D.; Perticone F.; Cimellaro A.; Filardi P.P.; Paolillo S.; Mancini A.; Volterrani M.; Vriz O.; Castello R.; Passantino A.; Campo M.; Modesti P.A.; de Giorgi A.; Monte I.P.; Puzzo A.; Ballotta A.; D'Assante R.; Arcopinto M.; Gargiulo P.; Sciacqua A.; Bruzzese D.; Colao A.; Napoli R.; Suzuki T.; Eagle K.A.; Ventura H.O.; Marra A.M.; Bossone E.; Marra A.M.; Arcopinto M.; D'Assante R.; Sacca L.; Monti M.G.; Napoli R.; Matarazzo M.; Stagnaro F.M.; Piccioli L.; Lombardi A.; Panicara V.; Flora M.; Golia L.; Faga V.; Ruocco A.; della Polla D.; Franco R.; Schiavo A.; Gigante A.; Spina E.; Sicuranza M.; Monaco F.; Apicella M.; Miele C.; Campanino A.G.; Mazza L.; Abete R.; Farro A.; Luciano F.; Polizzi R.; Ferrillo G.; de Luca M.; Crisci G.; Giardino F.; Barbato M.; Ranieri B.; Bossone E.; Ferrara F.; Russo V.; Malinconico M.; Citro R.; Guastalamacchia E.; Leone M.; Giagulli V.A.; Amarelli C.; Mattucci I.; Calabro P.; Calabro R.; D'Andrea A.; Maddaloni V.; Pacileo G.; Scarafile R.; Belfiore A.; Sciacqua A.; Casaretti L.; Gargiulo P.; Favuzzi A.M.R.; Di Segni C.; Bruno C.; Vergani E.; Massaro R.; Grimaldi F.; Frigo A.; Sorrentino M.R.; Malandrino D.; Manfredini R.; Fabbian F.; Ragusa L.; Caliendo L.; Carbone L.; Frigiola A.; Generali T.; Giacomazzi F.; de Vincentiis C.; Garofalo P.; Malizia G.; Milano S.; Misiano G.; Suzuki T.; Israr M.Z.; Bernieh D.; Cassambai S.; Yazaki Y.; Heaney L.M.; Eagle K.A.; Ventura H.O.; Colao A.; Bruzzese D.. - In: EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY. - ISSN 2047-4873. - STAMPA. - 28:(2021), pp. 1691-1700. [10.1093/eurjpc/zwab020]

Multiple hormonal and metabolic deficiency syndrome predicts outcome in heart failure: the T.O.S.CA. Registry

Modesti P. A.
Investigation
;
Malandrino D.;
2021

Abstract

Aims Recent evidence supports the occurrence of multiple hormonal and metabolic deficiency syndrome (MHDS) in chronic heart failure (CHF). However, no large observational study has unequivocally demonstrated its impact on CHF progression and outcome. The T.O.S.CA. (Trattamento Ormonale nello Scompenso CArdiaco; Hormone Treatment in Heart Failure) Registry has been specifically designed to test the hypothesis that MHDS affects morbidity and mortality in CHF patients. Methods The T.O.S.CA. Registry is a prospective, multicentre, observational study involving 19 Italian centres. Thyroid and Results hormones, insulin-like growth factor-1, total testosterone, dehydropianoandrosterone sulfate, insulin resistance, and the presence of diabetes were evaluated. A MHDS was defined as the presence of ≥2 hormone deficiencies (HDs). Primary endpoint was a composite of all-cause mortality and cardiovascular hospitalizations. Four hundred and eighty heart failure patients with ejection fraction ≤45% were enrolled. MHDS or diabetes was diagnosed in 372 patients (77.5%). A total of 271 events (97 deaths and 174 cardiovascular hospitalizations) were recorded, 41% in NO-MHDS and 62% in MHDS (P < 0.001). Median follow-up was of 36 months. MHDS was independently associated with the occurrence of the primary endpoint [hazard ratio 95% (confidence interval), 1.93 (1.37–2.73), P < 0.001] and identified a group of patients with a higher mortality [2.2 (1.28–3.83), P = 0.01], with a graded relation between HDs and cumulative events (P < 0.01). Conclusion MHDS is common in CHF and independently associated with increased all-cause mortality and cardiovascular hospitalization, representing a promising therapeutic target.
2021
28
1691
1700
Cittadini A.; Salzano A.; Iacoviello M.; Triggiani V.; Rengo G.; Cacciatore F.; Maiello C.; Limongelli G.; Masarone D.; Perticone F.; Cimellaro A.; Filardi P.P.; Paolillo S.; Mancini A.; Volterrani M.; Vriz O.; Castello R.; Passantino A.; Campo M.; Modesti P.A.; de Giorgi A.; Monte I.P.; Puzzo A.; Ballotta A.; D'Assante R.; Arcopinto M.; Gargiulo P.; Sciacqua A.; Bruzzese D.; Colao A.; Napoli R.; Suzuki T.; Eagle K.A.; Ventura H.O.; Marra A.M.; Bossone E.; Marra A.M.; Arcopinto M.; D'Assante R.; Sacca L.; Monti M.G.; Napoli R.; Matarazzo M.; Stagnaro F.M.; Piccioli L.; Lombardi A.; Panicara V.; Flora M.; Golia L.; Faga V.; Ruocco A.; della Polla D.; Franco R.; Schiavo A.; Gigante A.; Spina E.; Sicuranza M.; Monaco F.; Apicella M.; Miele C.; Campanino A.G.; Mazza L.; Abete R.; Farro A.; Luciano F.; Polizzi R.; Ferrillo G.; de Luca M.; Crisci G.; Giardino F.; Barbato M.; Ranieri B.; Bossone E.; Ferrara F.; Russo V.; Malinconico M.; Citro R.; Guastalamacchia E.; Leone M.; Giagulli V.A.; Amarelli C.; Mattucci I.; Calabro P.; Calabro R.; D'Andrea A.; Maddaloni V.; Pacileo G.; Scarafile R.; Belfiore A.; Sciacqua A.; Casaretti L.; Gargiulo P.; Favuzzi A.M.R.; Di Segni C.; Bruno C.; Vergani E.; Massaro R.; Grimaldi F.; Frigo A.; Sorrentino M.R.; Malandrino D.; Manfredini R.; Fabbian F.; Ragusa L.; Caliendo L.; Carbone L.; Frigiola A.; Generali T.; Giacomazzi F.; de Vincentiis C.; Garofalo P.; Malizia G.; Milano S.; Misiano G.; Suzuki T.; Israr M.Z.; Bernieh D.; Cassambai S.; Yazaki Y.; Heaney L.M.; Eagle K.A.; Ventura H.O.; Colao A.; Bruzzese D.
File in questo prodotto:
File Dimensione Formato  
2021 - European Journal of Preventive Cardiology (2021) 28, 1691–1700.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 624.93 kB
Formato Adobe PDF
624.93 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1258241
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 21
social impact